ReviewJournal of enzyme inhibition and medicinal chemistry2023
Research progress of natural products and their derivatives against Alzheimer's disease.
Review in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Mechanistic study on the alleviating effects of cinnamaldehyde on aluminum chloride-induced cognitive impairment in zebrafish through modulating the TLR4/NF-κB signaling pathway.Metabolic brain disease · 2026Article
- Machine Learning-Integrated Pharmacophore, DFT Analysis, and molecular dynamics of Diosmetin as a potent ache inhibitor with neuroprotective activity in a Scopolamine-Induced alzheimer's zebrafish model.Journal of computer-aided molecular design · 2026Article
- Dihydrotanshinone as a Natural Product-Based CYP17A1 Lyase Inhibitor for Hyperandrogenic Disorders.Biomolecules · 2026Article
- Natural Chiral Scaffolds in Alzheimer's Disease: Therapeutic Potential, Mechanism, and Clinical Aspects.BioMed research international · 2026Review
- Research Progress on the Pathogenesis, Therapeutic Strategies, and Phthalocyanine Compounds for Alzheimer's Disease.Current Alzheimer research · 2026Review
- Pharmacological mechanisms of natural products with antidepressant effects: A focus on the programmed cell death regulation.Journal of pharmaceutical analysis · 2026Review
- The Neuroprotective Potential ofNutrients · 2025Review
- The global patent landscape of the drugs for treating Alzheimer's disease from 2014-2023.BMC neurology · 2025Article
- Neuroactive Phytoconstituents ofCurrent topics in medicinal chemistry · 2025Review
- Troxerutin attenuates LPS-induced inflammation in BV2 microglial cells involving Nrf2 activation and NF-κB pathway inhibition.Iranian journal of basic medical sciences · 2025Article
- Therapeutic Options in Alzheimer's Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic Activity.Life (Basel, Switzerland) · 2024Article
- Phikud navakot extract acts as an ER stress inhibitor to ameliorate ER stress and neuroinflammation.Heliyon · 2024Article
- Article
- Protective signature of xanthohumol on cognitive function of APP/PS1 mice: a urine metabolomics approach by age.Frontiers in pharmacology · 2024Article
- Harnessing the Bioactive Potential ofPlants (Basel, Switzerland) · 2023Article
- Past, present, and future of deep transcranial magnetic stimulation: A review in psychiatric and neurological disorders.World journal of psychiatry · 2023Review
- Neuroprotective Iridoids and Lignans fromMolecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD), a persistent neurological dysfunction, has an increasing prevalence with the aging of the world and seriously threatens the health of the elderly. Although there is currently no effective treatment for AD, researchers have not given up, and are committed to exploring the pathogenesis of AD and possible therapeutic drugs. Natural products have attracted considerable attention owing to their unique advantages. One molecule can interact with multiple AD-related targets, thus having the potential to be developed in a multi-target drug. In addition, they are amenable to structural modifications to increase interaction and decrease toxicity. Therefore, natural products and their derivatives that ameliorate pathological changes in AD should be intensively and extensively studied. This review mainly presents research on natural products and their derivatives for the treatment of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.